Actively Recruiting

Age: 18Years +
All Genders
Healthy Volunteers
ID06395129

Implementing a Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries: a Process and Outcome Evaluation

Led by Médecins du Monde · Updated on 2025-10-01

2400

Participants Needed

9

Research Sites

N/A

Total Duration

On this page

Sponsors

M

Médecins du Monde

Lead Sponsor

U

UNITAID

Collaborating Sponsor

AI-Summary

What this Trial Is About

The trial investigates the implementation and evaluation of a distribution program for low dead-space syringes and needles (LDSS/N) among people who inject drugs across multiple low- and middle-income countries. The study aims to provide evidence on how best to run LDSS/N distribution programs to improve acceptability and maintain high usage levels, potentially reducing transmission of blood borne viruses such as HIV and hepatitis C. This observational study involves participants who access needle and syringe programs (NSPs) at existing sites. The study includes three phases: initially, focus group discussions (FGDs) will gather participant feedback on various LDSS/N products to guide selection for pilot distribution. Then, over a 6-week pilot period, participants will use the selected LDSS/N products alongside usual NSP services. Finally, a scaled-up distribution of selected LDSS/N products will be offered at study sites, with routine program data collection and a concurrent observational cohort study running alongside. Participants in the cohort will undergo HIV and HCV testing and complete surveys at baseline, 6, 12, and 18 months. Participants will be engaged through multiple FGDs to discuss their experiences and preferences with LDSS/N products at different stages. The cohort study involves repeated HIV and HCV antibody testing and behavioral surveys to assess uptake and impact over 18 months. Additional data collection includes routine program records and interviews with staff and stakeholders to evaluate program feasibility and effectiveness. The study will also use mathematical modeling to estimate the public health impact and cost-effectiveness of LDSS/N distribution in these settings.

CONDITIONS

Brief Title

Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries

Who Can Participate

Age: 18Years +
All Genders
Healthy Volunteers

Eligibility Criteria

Eligible

You may qualify if you...

  • Aged 18 years or older (some countries may include participants aged 16 and above)
  • Report recent injection drug use within the past month
  • Access needle and syringe programs (NSP) at facilities, mobile services, or outreach with a program ID
  • Able to understand and communicate in the local language(s)
  • If self-reporting HIV and hepatitis C negative status, willing to undergo testing
  • Willing and able to provide informed consent to participate
Not Eligible

You will not qualify if you...

History of severe allergic reactions to study medication Currently pregnant or breastfeeding Recent participation in another clinical trial within the last 30 days Presence of uncontrolled medical conditions that could affect safety

AI-Screening

AI-Powered Screening

Complete this quick 3-step screening to check your eligibility

1
2
3
+1

Your Study Journey

Screening

Duration - 2 to 4 weeks

Participants are screened for eligibility to participate in the trial.

1 visit (in-person)

Diagnostic Evaluation

Duration - At baseline

Participants undergo HIV and Hepatitis C antibody testing and complete surveys on demographic and behavioral activities to establish baseline information.

1 visit (in-person)

Implementation

Duration - 6 weeks

Participants have access to low dead-space syringes and needles alongside usual needle and syringe program services during a 6-week pilot period. They also participate in focus group discussions to provide feedback on the products.

Access during usual visits and 2 focus group discussions

Long-term Monitoring

Duration - 18 months

Participants are followed over 18 months with repeated HIV and Hepatitis C testing and surveys at 6, 12, and 18 months to monitor uptake and impact of the low dead-space syringes and needles.

Up to 4 visits (baseline, 6, 12, and 18 months)

Surveillance

Duration - Concurrent with other stages

Routine programmatic data is collected anonymously from individuals accessing study sites to monitor ongoing use of low dead-space syringes and needles.

Data collected during routine service visits

Trial Site Locations

Total: 9 locations

1

Real World Real People

Yerevan, Armenia

Actively Recruiting

2

Step to Future

Gori, Georgia

Actively Recruiting

3

New Vector

Rustavi, Georgia

Actively Recruiting

4

Hepa+

Tbilisi, Georgia

Actively Recruiting

5

Mukikute

Dar es Salaam, Tanzania

Actively Recruiting

6

Peer 2 Peer

Dar es Salaam, Tanzania

Actively Recruiting

7

Yovaribe

Ilala, Tanzania

Actively Recruiting

8

Mefada

Kinondoni, Tanzania

Actively Recruiting

9

STEPS Tanzania

Ubungo, Tanzania

Actively Recruiting

Loading map...

Research Team

B

Bridget Draper

M

Mark Stoové

How is the study designed?

Study Type

OBSERVATIONAL

Masking

N/A

Allocation

N/A

Model

N/A

Primary Purpose

N/A

Number of Arms

1

Similar Trials

#AWARE.HIV Europe: Supporting Healthcare Professionals to Fi...

HIV Infection

Actively Recruiting

28 locations

1MoreStep: Pilot Trial of an Intervention to Increase HIV Ca...

Violence, Domestic

Actively Recruiting

1 location

Frequently Asked Questions

Have more questions? Get in touch with our team for quick support

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here